Disappointment and despair are mounting in the MAHA movement after the Food and Drug Administration (FDA) approved Moderna’s controversial mRNA flu shot. Several top FDA officials—Dr. Marty Makary, Dr. Vinay Prasad, and Dr. Tracy Beth Hoeg—are no longer with the FDA after initially refusing to review Moderna’s mRNA product back in February.

Makary resigned as FDA Commissioner on May 12, reportedly due to a dispute with the White House over flavored e-cigarettes. A White House official told FOX News back in May that Makary’s resignation was about “process at the FDA” and that there was “no bad blood” between Makary and President Donald Trump.

Hoeg, acting director of the Center for Drug Evaluation and Research, was fired in May 2026 following Makary’s exit. Hoeg, a key ally of Health and Human Services (HHS) Secretary Robert Kennedy Jr., was known for her vaccine skepticism, and opposition to COVID-19 injections for children.

Prasad resigned as head of the Center for Biologics Evaluation and Research (CBER) in April following intense scrutiny and criticism from drug-makers, patients, and President Trump over his refusal to rush through several rare disease gene therapies and his efforts to enforce stricter safety reviews for vaccines.

Prasad was previously forced out of office in July 2025 after less than three months in office, following a dispute over the gene therapy Elevidys and intense pressure from the White House. He was reinstated just two weeks later in August 2025 at the request of FDA leadership and Health Secretary Robert F. Kennedy Jr.

David Kaslow MD, who replaced Prasad at CBER, approved Moderna’s mRNA flu shot on Aug. 5.

Prior to joining the FDA, Dr. Kaslow was the Chief Scientific Officer and Vice President of Essential Medicines at PATH, an international global health organization heavily funded by the Bill & Melinda Gates foundation and based in Seattle, Washington.

The mFlusiva shot was approved on an accelerated basis, meaning Moderna only needed to submit preliminary, short-term data. The full study doesn’t end until 2030.

Vaccine critics say that among other “egregious subterfuges, cheats and poor design practices” in Moderna’s clinical trial, the company didn’t use a true placebo, but instead compared the mRNA shot to a traditional flu vaccine, in other words they compared “one bad vaccine with another.”

In a phase 3 trial of over 40,000 people aged 50 or older, the Moderna mRNA shot demonstrated slightly better (0.8 percent) vaccine efficacy versus the traditional vaccine, but recipients suffered significantly higher adverse events.

Nearly two-thirds (65.8 percent) of mFlusiva recipients experienced injection-site pain, compared to roughly 30–34 percent for the traditional vaccine. Approximately 45 percent reported fatigue and 38 percent reported headaches after the Moderna shot—nearly twice as many cases of fatigue and headaches observed in traditional vaccines.

Muscle pain, joint pain, and chills were also more frequent in the mFlusiva group.

Serious events linked to the Moderna vaccine included a case of fainting, a case of low blood pressure that led to a three-day hospitalization and a case of perimyocarditis, or inflammation of the lining of the heart and the heart muscle.

A concerning number of recipients suffered serious adverse events (SAE) likely requiring hospitalization, according to the trial data analyzed by medical investigative journalist Maryanne Demasi, PHD.

The six-month data show that 449 participants in the mRNA group experienced at least one SAE, compared with 389 in the conventional group—an excess of 60 people.

So, while the pivotal trial showed there were 4 fewer influenza hospitalisations in the mRNA group, 60 additional people experienced an SAE.

SAEs are not mild events—they are usually severe enough to require hospitalisation, threaten life, cause significant disability, or result in death.

The imbalance of SAEs in Moderna’s pivotal trial was statistically significant—meaning it was unlikely to be a random fluke.

Demasi argues in her Substack report that the FDA used a “statistical sleight-of-hand” to make the significant safely signals in Moderna’s flu shot disappear.

“Vaccine regulation is broken,” Dr. Joseph A. Ladapo, the surgeon general of Florida, lamented on X.

Vaccine safety advocate Steve Kirsch commented on X that Moderna’s flu vaccine “is not going to save your life, but it might kill you.”

The Brownstone Institute’s Dr. Toby Rogers summed up on X what many vaccine critics have been saying about Moderna’s latest mRNA shot:

• Far more harms than benefits.
• Will kill thousands of seniors every year.
• The regulatory decision was purchased via a big donation to the GOP.
• Sec. Kennedy was humiliated, again.
• The vaccinated will shed on us.

Rogers called “Operation Warp Speed,” the Trump administration’s well intentioned but misguided effort to speed up the development of the COVID vaccines in 2020, “the most egregious crime in U.S. history.”

The Moderna mRNA flu shot is worse. It institutionalizes the carnage of the COVID vaccine holocaust via annual flu shots. The purpose of these shots is to increase disease and thereby increase profits for Pharma.

Many in the “MAHA” movement are now questioning why Kennedy,  a staunch critic of mRNA technology who has called the COVID injections “the deadliest vaccine ever made,” would allow this to happen.

Under RFK Jr., Health and Human Services HHS last year canceled nearly $500 million in funding for mRNA vaccine research, but Big Pharma appears to have powerful allies in the Trump administration.

When asked about Kennedy’s opinion on mFlusiva’s approval, a spokesperson for HHS said: “Secretary Kennedy has been clear that he believes mRNA products warrant heightened scientific scrutiny. That’s why this vaccine is entering the market with some of the strongest post-market study commitments FDA has required, particularly for individuals 65 years of age and older.”